StreetInsider.com News Articles

Nxera Pharma Webinar for Financial Results Presentation - 2Q2026

Wed, 15 Jul 2026 05:13:00 -0400

Tokyo, Japan and Cambridge and London, UK, 15 July 2026 – Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for 2Q 2026 on Friday, 7 August 2026.

The Company will host a live webinar presentation with Chris Cargill (President, CEO), Hironoshin Nomura (CFO), Toshi Maeda (COO) and Patrik Foerch (CSO and President of Nxera Pharma UK), at 5:00 pm JST (9:00 am GMT) on Friday, 7 August 2026.

The webinar is open to all existing and potential investors as well as sell-/buy-side analysts and will consist of a presentation followed by a Q&A session.

Nxera Pharma Webinar for Financial Results Presentation - 2Q2026

Wed, 15 Jul 2026 05:13:00 -0400

Nxera Pharma Webinar for Financial Results Presentation - 2Q2026

Wed, 15 Jul 2026 05:13:00 -0400

Nxera Pharma Webinar for Financial Results Presentation - 2Q2026

Wed, 15 Jul 2026 05:13:00 -0400

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Tue, 30 Jun 2026 04:27:00 -0400

This marks the fourth R&D milestone achieved under the collaboration, and the second in 2026, reflecting the steady progress of development under the collaboration
Under the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, development and commercial milestones, in addition to tiered royalties based on sales

Tokyo, Japan and Cambridge and London, UK, 30 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a fourth R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Tue, 30 Jun 2026 04:27:00 -0400

This marks the fourth R&D milestone achieved under the collaboration, and the second in 2026, reflecting the steady progress of development under the collaboration
Under the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, development and commercial milestones, in addition to tiered royalties based on sales

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Tue, 30 Jun 2026 04:27:00 -0400

This marks the fourth R&D milestone achieved under the collaboration, and the second in 2026, reflecting the steady progress of development under the collaboration
Under the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, development and commercial milestones, in addition to tiered royalties based on sales

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Tue, 30 Jun 2026 04:27:00 -0400

This marks the fourth R&D milestone achieved under the collaboration, and the second in 2026, reflecting the steady progress of development under the collaboration
Under the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, development and commercial milestones, in addition to tiered royalties based on sales

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Wed, 10 Jun 2026 02:35:00 -0400

Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery. Technology companies, including Amazon Web Services, Microsoft and NVIDIA, participate in OpenFold as supporting members and the consortium has expanded into an international ecosystem comprising numerous pharmaceutical companies, biotechnology companies, technology companies and academic institutions, including Bristol Myers Squibb, Novo Nordisk, Bayer and Roche.